Cytek Biosciences (CTKB) AI Stock Analysis

• Market Cap: $510.17M
• Dividend Yield: N/A
• Average Volume (3M): 1.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.74
• Revenue Growth: -0.85%
• EPS Growth: 61.31%
• Country: US
• Employees: 663
• Sector: Healthcare
• Sector Strength: 50
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 127,223,780
• 10 Day Avg. Volume: 1,309,726
• 30 Day Avg. Volume: 1,110,330
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.40
• Enterprise Value/Revenue: 1.04
• Enterprise Value/Gross Profit: 1.91
• Enterprise Value/Ebitda: -23.92
• 1Y Price Target: $5.33
• Price Target Upside: 31.93% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 54 Neutral
• Price Target: $4.50 ▲(11.39% Upside)

The overall stock score is primarily influenced by financial performance challenges, including declining revenue and profitability. Technical analysis shows positive momentum, but valuation concerns due to negative P/E ratio and lack of dividend yield weigh down the score.

Positive Factors

Product Launch

The launch of the Cytek Aurora Evo system, with improvements tailored to the pharma end market, presents new opportunities.

Recurring Revenue

Recurring revenue maintained positive momentum, with both services and consumables growing 18% year over year.

Service Revenue

Service and reagent revenue outperformance is a bright spot, with both growing 18% in Q2.

Negative Factors

Market Conditions

The flow cytometry market may be contracting or at least stagnating, making FY25 a difficult year to operate.

Product Revenue

Product revenue decreased due to academic funding uncertainty in the US and pressure on government budgets in EMEA.

Revenue and Margins

Multiple ongoing headwinds, such as NIH budgets, China, tariffs, and biopharma funding, continue to impact revenues and margins this year.

Cytek Biosciences Business Overview & Revenue Model

Company Description

Cytek Biosciences (CTKB) is a biotechnology company that specializes in the development and manufacturing of flow cytometry products. The company operates in the life sciences and healthcare sectors, providing advanced cell analysis systems and related reagents and software. Cytek's core products are designed to offer comprehensive and high-dimensional cell analysis solutions, which are utilized in various applications including immunology, cancer research, and drug discovery.

How the Company Makes Money

Cytek Biosciences generates revenue primarily through the sale of its flow cytometry systems, which include hardware, software, and associated reagents. The company offers a range of products tailored to different research and clinical needs, allowing it to cater to a wide customer base, including academic institutions, pharmaceutical companies, and clinical research organizations. In addition to product sales, Cytek may also derive income from service contracts, maintenance agreements, and training programs. Strategic partnerships and collaborations with other companies and research institutions can further contribute to its earnings by expanding its market reach and driving product innovation.

Cytek Biosciences Financial Statement Overview

Summary

Cytek Biosciences demonstrates strength in gross profitability and a solid balance sheet with low leverage. However, challenges persist in achieving net profitability and consistent positive cash flow. The company's high equity ratio and robust cash position provide stability, while improvements in net margins and cash flow consistency are needed to enhance financial health.

Income Statement

The company has shown a fluctuating revenue trend with a recent decline in TTM revenue. Gross profit margins remained strong at approximately 55%. However, net profit margins are negative due to persistent net losses. Despite a negative EBIT margin, the company maintains a relatively stable EBITDA margin due to lower depreciation and amortization costs. Overall, the income statement reflects a mix of stable gross profitability but challenges in achieving net profitability.

Balance Sheet

The balance sheet is marked by a strong equity position with a high equity ratio of 78.7%, indicating financial stability. The debt-to-equity ratio is very low, signifying minimal leverage usage. Despite the strong equity position, return on equity is negative due to net losses. The company maintains a robust cash position, which supports its financial resilience.

Cash Flow

The cash flow statement indicates a positive free cash flow in the TTM period, recovering from negative cash flows in prior years. Operating cash flow to net income ratio is positive, highlighting efficient cash generation relative to net losses. However, free cash flow to net income ratio remains challenged due to substantial capital expenditures in previous years. Overall, cash flows show improvement, but consistent generation of positive free cash flow is required for stronger performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	196.03M	200.45M	193.01M	164.04M	127.95M	92.84M
Gross Profit	106.68M	111.11M	109.43M	100.97M	79.14M	51.71M
EBITDA	-8.51M	-10.03M	-4.41M	9.54M	10.40M	15.37M
Net Income	-6.40M	-6.02M	-12.15M	2.58M	4.42M	19.41M
Balance Sheet
Total Assets	493.32M	499.50M	494.46M	519.48M	463.70M	219.98M
Cash, Cash Equivalents and Short-Term Investments	262.02M	277.86M	262.41M	341.15M	364.62M	165.23M
Total Debt	14.12M	17.02M	14.14M	18.09M	0.00	2.77M
Total Liabilities	115.76M	103.76M	101.39M	93.93M	56.90M	236.01M
Stockholders Equity	377.56M	395.74M	393.06M	425.30M	406.46M	-16.03M
Cash Flow
Free Cash Flow	11.06M	21.85M	454.00K	-22.10M	266.00K	13.61M
Operating Cash Flow	15.20M	25.38M	5.28M	-12.23M	4.63M	15.16M
Investing Cash Flow	-86.20M	-82.97M	-93.89M	-55.91M	-20.99M	-1.55M
Financing Cash Flow	-29.87M	-15.82M	-41.81M	5.51M	213.56M	122.61M

Cytek Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTKB, the sentiment is Positive. The current price of 4.04 is above the 20-day moving average (MA) of 3.82, above the 50-day MA of 3.54, and below the 200-day MA of 4.60, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 59.57 is Neutral, neither overbought nor oversold. The STOCH value of 69.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTKB.

Cytek Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$19.67B	4.59	-1.49%	3.27%	11.25%	-16.57%
SGHT	58 Neutral	$219.42M	―	-57.10%	―	-3.89%	9.68%
CTKB	54 Neutral	$510.17M	―	-1.67%	―	-0.85%	61.31%
MASS	51 Neutral	$226.26M	―	-46.85%	―	14.65%	-86.36%
TLSI	47 Neutral	$242.35M	―	271.41%	―	45.50%	53.07%
PACB	46 Neutral	$399.49M	―	-189.52%	―	-17.35%	-19.34%
BFLY	44 Neutral	$362.51M	―	-29.42%	―	23.13%	46.62%

Cytek Biosciences Corporate Events

Cytek Biosciences Elects New Directors at Annual Meeting

On June 18, 2025, Cytek Biosciences held its annual meeting of stockholders, with approximately 81.4% of outstanding shares represented. During the meeting, Richard Chin, MD, and Deborah Neff were elected as Class I directors to serve until 2028. Additionally, the executive compensation for 2024 was approved, and Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2025.

The most recent analyst rating on (CTKB) stock is a Buy with a $8.25 price target. To see the full list of analyst forecasts on Cytek Biosciences stock, see the CTKB Stock Forecast page.